EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022
http://www.reportlinker.com/p01163176/EpiCast-Report-Idiopathic-Pulmonary-Fibrosis---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022

Summary

Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults and is associated with a histologic and/or radiologic pattern of usual interstitial pneumonia (NHLBI, 2011; Raghu et al., 2011). As a fatal disease that falls under the umbrella of interstitial lung disease of unknown cause, IPF is limited to the lungs and manifests with irreversible and variable scarring, stiffening, and thickening of the lung tissues that leads to progressively worsening of pulmonary function (NHLBI, 2011; Raghu et al. 2011). IPF is the most common form of idiopathic interstitial pneumonia and also has the worst prognosis, with only three to five years of median survival (Olson and Swigris, 2012). Respiratory failure accounts for over 80% of IPF fatalities (Raghu et al., 2006). IPF is more common in men, and its prevalence typically increases with advancing age.

GlobalData forecasts that there will be 45,718 incident cases of IPF in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK) in 2022, with an Annual Growth Rate (AGR) of 2.01% during 2012–2022. By 2022, there will be 88,357 prevalent cases of IPF in the 6MM. Changes in the population structure and population growth will be the major drivers of the observed increase in the incident and prevalent cases of IPF. In addition to population growth, further industrialization or other circumstances that could increase exposure to potential risk factors for the disease could also drive the increase in the incident and prevalent cases of IPF. The emergence of new evidence and a better understanding of the pathogenesis and biology of IPF will possibly help in detecting IPF in the preclinical and early stages and in improving treatment, outcomes, and prognosis.

Scope

- The Idiopathic Pulmonary Fibrosis (IPF) EpiCast Report provides an overview of the risk factors and global trends of IPF in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK).
- It includes a 10-year epidemiology forecast of the incident and prevalent cases of IPF segmented by sex and age (by five-year increments, beginning at age 50 years and ending at age 85 years and older) in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global IPF market.
- Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IPF therapeutics in each of the markets covered.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 There is almost no risk of IPF among long-term heavy smokers 11
3.2.2 Common workplace inhalant pose a large risk in many occupations 11
3.2.3 Gastroesophageal reflux (GER) is common in IPF patients 12
3.3 Global Trends 13
3.3.1 US 13
3.3.2 5EU 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 16
3.4.2 Forecast Assumptions and Methods 18
3.4.3 Sources Not Used 21
3.5 Epidemiology Forecast of Idiopathic Pulmonary Fibrosis (2012–2022) 23
3.5.1 Total Incident Cases of Idiopathic Pulmonary Fibrosis 23
3.5.2 Age-Specific Incident Cases of Idiopathic Pulmonary Fibrosis 25
3.5.3 Sex-Specific Incident Cases of Idiopathic Pulmonary Fibrosis 26
3.5.4 Total Prevalent Cases of Idiopathic Pulmonary Fibrosis 27
3.5.5 Age-Specific Prevalent Cases of Idiopathic Pulmonary Fibrosis 29
3.5.6 Sex-Specific Prevalent Cases of Idiopathic Pulmonary Fibrosis 31
3.6 Discussion 33
3.6.1 Conclusions on Epidemiology Trends 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 34
4 Appendix 35
4.1 Bibliography 35
4.2 About the Authors 37
4.2.1 Epidemiologists 37
4.2.2 Reviewers 37
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 39
4.2.4 Global Head of Healthcare 39
4.3 About GlobalData 40
4.4 About EpiCast 40
4.5 Contact Us 40
4.6 Disclaimer 41

List of Tables

Table 1: Risk Factors and Comorbidities for Idiopathic Pulmonary Fibrosis 10
Table 2: 6MM, Sources of Prevalence and Incidence Data Used in the Idiopathic Pulmonary Fibrosis Epidemiological Forecast 16
Table 3: 6MM, Incident Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, Men and Women, N, Selected Years, 2012–2022 23
Table 4: 6MM, Incident Cases of Idiopathic Pulmonary Fibrosis, By Age*, Men and Women, N (Row %), 2012 25
Table 5: 6MM, Incident Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, By Sex, N (Row %), 2012 26
Table 6: 6MM, Prevalent Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, Men and Women, N, Selected Years, 2012–2022 28
Table 7: 6MM, Prevalent Cases of Idiopathic Pulmonary Fibrosis, By Age*, Men and Women, N (Row %), 2012 29
Table 8: 6MM, Prevalent Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, By Sex, N (Row %), 2012 31

List of Figures

Figure 1: 6MM, Incident Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, Men and Women, N, Selected Years, 2012–2022 24
Figure 2: 6MM, Incident Cases of Idiopathic Pulmonary Fibrosis, By Age*, Men and Women, N, 2012 26
Figure 3: 6MM, Incident Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, By Sex, N, 2012 27
Figure 4: 6MM, Prevalent Cases of Idiopathic Pulmonary Fibrosis, Ages ? 50 Years, Men and Women, N, Selected Years, 2012–2022 28
Figure 5: 6MM, Prevalent Cases of Idiopathic Pulmonary Fibrosis, By Age*, Men and Women, N, 2012 30
Figure 6: Six Major Markets, Prevalent Cases of Idiopathic Pulmonary Fibrosis, Ages ?50 Years, By Sex, N, 2012 32

To order this report:
General_Medicine_and_Specialty_Medicine Industry: EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker